Literature DB >> 17414088

Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.

Ednan K Bajwa1, Chu-Ling Yu, Michelle N Gong, B Taylor Thompson, David C Christiani.   

Abstract

OBJECTIVE: Pre-B-cell colony-enhancing factor (PBEF) levels are elevated in bronchoalveolar lavage fluid and serum of patients with acute lung injury. There are several suspected functional polymorphisms of the corresponding PBEF gene. We hypothesized that variations in PBEF gene polymorphisms alter the risk of developing acute respiratory distress syndrome (ARDS).
DESIGN: Nested case-control study.
SETTING: Tertiary academic medical center. PATIENTS: We studied 375 patients with ARDS and 787 at-risk controls genotyped for the PBEF T-1001G and C-1543T polymorphisms.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Patients with the -1001G (variant) allele had significantly greater odds of developing ARDS than wild-type homozygotes (odds ratio, 1.35; 95% confidence interval, 1.02-1.78). Patients with the -1543T (variant) allele did not have significantly different odds of developing ARDS than wild-type homozygotes (odds ratio, 0.86; 95% confidence interval, 0.65-1.13). When analysis was stratified by ARDS risk factor, -1543T was associated with decreased odds of developing ARDS in septic shock patients (odds ratio, 0.66; 95% confidence interval, 0.45-0.97). Also, -1001G was associated with increased hazard of intensive care unit mortality, whereas -1543T was associated with decreased hazard of 28-day and 60-day ARDS mortality, as well as shorter duration of mechanical ventilation. Similar results were found in analyses of the related GC (-1001G:-1543C) and TT (-1001T:-1543T) haplotypes.
CONCLUSIONS: The PBEFT-1001G variant allele and related haplotype are associated with increased odds of developing ARDS and increased hazard of intensive care unit mortality among at-risk patients, whereas the C-1543T variant allele and related haplotype are associated with decreased odds of ARDS among patients with septic shock and better outcomes among patients with ARDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414088     DOI: 10.1097/01.CCM.0000260243.22758.4F

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  52 in total

1.  Nicotinamide Phosphoribosyltransferase in Human Diseases.

Authors:  Li Qin Zhang; Daniel P Heruth; Shui Qing Ye
Journal:  J Bioanal Biomed       Date:  2011-01-07

Review 2.  Recent advances in genetic predisposition to clinical acute lung injury.

Authors:  Li Gao; Kathleen C Barnes
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-13       Impact factor: 5.464

3.  Genomic investigations into acute inflammatory lung injury.

Authors:  Joe G N Garcia
Journal:  Proc Am Thorac Soc       Date:  2011-05

4.  Focusing on the flood: targeting functional polymorphisms in ALI permeability pathways.

Authors:  Joe G N Garcia
Journal:  Am J Respir Crit Care Med       Date:  2011-05-15       Impact factor: 21.405

5.  Genomic and Genetic Approaches to Deciphering Acute Respiratory Distress Syndrome Risk and Mortality.

Authors:  Heather Lynn; Xiaoguang Sun; Nancy Casanova; Manuel Gonzales-Garay; Christian Bime; Joe G N Garcia
Journal:  Antioxid Redox Signal       Date:  2019-06-18       Impact factor: 8.401

6.  Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.

Authors:  Liliana Moreno-Vinasco; Hector Quijada; Saad Sammani; Jessica Siegler; Eleftheria Letsiou; Ryan Deaton; Laleh Saadat; Rafe S Zaidi; Joe Messana; Peter H Gann; Roberto F Machado; Wenli Ma; Sara M Camp; Ting Wang; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2014-08       Impact factor: 6.914

Review 7.  Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases.

Authors:  Shin-Ichiro Imai
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Body mass index is associated with the development of acute respiratory distress syndrome.

Authors:  M N Gong; E K Bajwa; B T Thompson; D C Christiani
Journal:  Thorax       Date:  2009-09-21       Impact factor: 9.139

9.  Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis.

Authors:  Shali Mazaki-Tovi; Edi Vaisbuch; Roberto Romero; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Chia-Ling Nhan-Chang; Ricardo Gomez; Bo H Yoon; Lami Yeo; Pooja Mittal; Giovanna Ogge; Juan M Gonzalez; Sonia S Hassan
Journal:  Am J Reprod Immunol       Date:  2010-01-19       Impact factor: 3.886

10.  Maternal visfatin concentration in normal pregnancy.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.